专利检索 cpc:"C07D513/10" 第 1 页

1.

发明授权
Compounds that inhibit MCL-1 protein 有权

公开(公告)号：US12091425B2

公开(公告)日：2024-09-17

申请号：US17501075

申请日：2021-10-14

申请人： AMGEN INC.

发明人： David Karl Bedke , Michael W. Gribble, Jr. , Michael G. Johnson , Todd J. Kohn , Kexue Li

IPC分类号： C07D513/10 , C07D513/20 , C07D515/10

CPC分类号： C07D513/10 , C07D513/20 , C07D515/10

摘要： Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

2.

发明公开
OREXIN RECEPTOR AGONISTS AND USES THEREOF 审中-公开

公开(公告)号：US20240254143A1

公开(公告)日：2024-08-01

申请号：US18558245

申请日：2022-05-03

申请人： JAZZ PHARMACEUTICALS IRELAND LIMITED

发明人： Prafulkumar CHOVATIA , Claudia BEATO , Gilles OUVRY , Davide MARINELLI

IPC分类号： C07D498/10 , C07D471/10 , C07D513/10 , C07D515/10

CPC分类号： C07D498/10 , C07D471/10 , C07D513/10 , C07D515/10

摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein n, m, A1, A2, A3, A4, A5, A6, L1, L2, R1, R2, R3, Y and Z are defined herein. Also provided herein are pharmaceutical compositions comprising a compound N of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a disease or disorder that is treatable by administration of an Orexin agonist.

3.

发明授权
Compounds that inhibit MCL-1 protein 有权

公开(公告)号：US12024529B2

公开(公告)日：2024-07-02

申请号：US18313703

申请日：2023-05-08

申请人： AMGEN INC.

发明人： Robert Farrell

IPC分类号： C07D249/18 , C07C59/56 , C07C59/68 , C07C311/11 , C07D498/00 , C07D513/08 , C07D513/10

CPC分类号： C07D513/10 , C07C59/56 , C07C59/68 , C07C311/11 , C07D249/18 , C07D498/00 , C07D513/08

摘要： Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

4.

发明公开
ANTI-VIRAL COMPOUNDS 审中-公开

公开(公告)号：US20240199647A1

公开(公告)日：2024-06-20

申请号：US18499941

申请日：2023-11-01

申请人： Aligos Therapeutics, Inc. , Katholieke Universiteit Leuven

发明人： Dorothée Alice Marie-Eve Bardiot , Sandro Boland , Arnaud Didier Marie Marchand , Koen Vandyck , David McGowan , Leonid Beigelman , Antitsa Dimitrova Stoycheva

IPC分类号： C07D513/10 , A61K45/06 , A61P31/14 , C07D471/10 , C07D487/10 , C07D487/20 , C07D498/10 , C07D498/20

CPC分类号： C07D513/10 , A61K45/06 , A61P31/14 , C07D471/10 , C07D487/10 , C07D487/20 , C07D498/10 , C07D498/20

摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

5.

发明申请
TRPA1 MODULATORS 审中-公开

公开(公告)号：US20190016701A1

公开(公告)日：2019-01-17

申请号：US15909652

申请日：2018-03-01

申请人： Algomedix, Inc.

发明人： Jeffrey M. Herz , Edward A. Kesicki

IPC分类号： C07D401/14 , C07D491/113 , A61K31/167 , C07D401/04 , C07D417/14 , C07D513/10 , C07D498/04 , C07D495/10 , C07D491/107 , C07D471/10 , C07D471/04 , C07D413/14 , C07D405/14 , A61K45/06 , A61K31/444 , A61K31/4045 , A61K31/415 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/485 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/513 , A61K31/536 , A61K31/537 , A61K31/538 , A61K31/635

CPC分类号： C07D401/14 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/46 , A61K31/485 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/4985 , A61K31/513 , A61K31/536 , A61K31/537 , A61K31/538 , A61K31/635 , A61K45/06 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D491/107 , C07D491/113 , C07D495/10 , C07D498/04 , C07D513/10 , A61K2300/00

摘要： This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.

6.

发明申请
1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS 审中-公开

公开(公告)号：US20180208607A1

公开(公告)日：2018-07-26

申请号：US15874987

申请日：2018-01-19

申请人： PFIZER INC.

发明人： MICHAEL AARON BRODNEY , CHRISTOPHER RYAN BUTLER , LAURA ANN MCALLISTER , CHRISTOPHER JOHN HELAL , STEVEN VICTOR O'NEIL , PATRICK ROBERT VERHOEST

IPC分类号： C07D513/10 , C07D221/20

CPC分类号： C07D513/10 , C07D221/20 , C07D295/185 , C07D401/08 , C07D401/12 , C07D491/10

摘要： The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

7.

发明申请
ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS 审中-公开

公开(公告)号：US20180044282A1

公开(公告)日：2018-02-15

申请号：US15688732

申请日：2017-08-28

申请人： FORMA Therapeutics, Inc.

发明人： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary Margaret Zablocki , Xiaozhang Zheng

IPC分类号： C07C259/06 , C07D471/04 , C07D417/04 , C07D241/08 , C07D213/56 , C07D233/68 , C07D235/14 , C07D487/10 , C07D471/10 , C07D295/155 , C07D209/44 , A61K31/5377 , A61K31/4439 , A61K31/495 , A61K31/44 , A61K31/417 , A61K31/4184 , A61K31/397 , C07D495/10 , A61K31/407 , A61K31/435 , A61K31/451 , A61K31/4035 , A61K31/277 , A61K31/438 , C07D221/20 , A61K31/185 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , C07D239/22 , C07D239/20 , C07D235/30 , C07D401/12 , C07D401/04 , C07D333/70 , C07D233/38 , C07D233/36 , C07D231/18 , C07D231/14 , C07D317/68 , C07D215/12 , C07D213/81 , C07D213/75 , C07D401/14

CPC分类号： C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10 , Y02A50/393 , Y02A50/411 , Y02A50/481

摘要： The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

8.

发明申请
Amido Compounds And Their Use As Pharmaceuticals 有权

公开(公告)号：US20170334847A1

公开(公告)日：2017-11-23

申请号：US15602693

申请日：2017-05-23

申请人： Incyte Corporation , Incyte Holdings Corporation

发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Colin Zhang , Brian W. Metcalf , Chunhong He , Ding-Quan Qian

IPC分类号： C07D207/06 , A61K31/407 , C07D495/04 , C07D493/10 , C07D491/20 , C07D491/107 , C07D491/10 , C07D487/10 , C07D487/08 , C07D487/04 , C07D471/10 , C07D471/04 , C07D417/04 , C07D413/14 , C07D413/10 , C07D405/14 , C07D405/04 , C07D403/04 , C07D401/14 , C07D401/10 , C07D401/06 , C07D401/04 , C07D333/34 , C07D295/185 , C07D221/20 , C07D217/26 , C07D217/06 , C07D213/38 , C07D211/70 , C07D211/66 , C07D211/64 , C07D211/58 , C07D211/52 , C07D211/48 , C07D211/46 , C07D211/34 , C07D211/22 , C07D211/18 , C07D211/16 , C07D209/70 , C07D209/62 , C07D209/52 , C07D209/44 , C07D209/42 , C07D209/08 , C07D207/27 , C07D207/16 , C07D207/14 , C07D207/12 , C07D207/10 , C07D207/08 , A61K31/4439 , C07D498/20 , C07D513/10

CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10

摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

9.

发明申请
2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) 审中-公开

公开(公告)号：US20170260185A1

公开(公告)日：2017-09-14

申请号：US15511420

申请日：2015-09-14

申请人： SHIRE INTERNATIONAL GMBH

发明人： Teresa SEMERARO , Luca TARSI , Fabrizio MICHELI , Tim LUKER , Susanna CREMONESI

IPC分类号： C07D471/10 , C07D498/10 , C07D513/10 , C07D491/20

CPC分类号： C07D471/10 , C07D491/20 , C07D498/10 , C07D513/10

摘要： The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.